Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Obamacare, Move From Fee-For-Service Boosts UnitedHealth By $2B

UnitedHealth Group (UNH) says its revenue this year will increase by $2 billion more than earlier projected for 2015 thanks in part to its expansion on public exchanges under the Affordable Care Act and its push to more value-based care contracts with doctors and hospitals. The outlook, which includes increased earnings projections for this year […]

Read More »

Aduro Biotech Launches $119 Million IPO with Hot Cancer Tech

BERKELEY, Calif.–(BUSINESS WIRE)–Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a price to the public of $17.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,050,000 shares of common stock at the initial […]

Read More »

Bayer HealthCare Invests $100 Million in East Bay Facility to Double Down on Hemophilia Drugs

April 14, 2015By Mark Terry, BioSpace.com Breaking News Staff Bayer HealthCare, a division of Germany-based Bayer AG (BAYZF), announced today that it will spend $100 million to expand its facilities near its campus in East Bay San Francisco. The new building will be 80,000-square-feet in size and will replace an older facility. The new build […]

Read More »

GlaxoSmithKline Sees Red at Design of Rival’s Purple Asthma Inhaler

GlaxoSmithKline (GSK) said Rowex Ltd is preparing to sell a product similar in its packaging to the “Seretide” inhaler and that this infringed its trademark. Seretide is the fourth-highest-selling pharmaceutical product in the world, with more than $62bn (€58bn) in global sales, including Ireland. The UK-based Glaxo Group, along with GSK (Ireland) Ltd, trading as […]

Read More »

AstraZeneca science is on the move, one year on from Pfizer bid

(Reuters) – Having seen off a hostile $118 billion bid launched a year ago by U.S. rival Pfizer, Anglo-Swedish company AstraZeneca is on the move — quite literally.  As of last month, a four-days-a-week service set up by the drugmaker with Sun Air is connecting staff in its new Cambridge science and operations hub with […]

Read More »

Strong Dollar Remains Headache For Johnson & Johnson

The continued climb of the U.S. dollar weighed heavily on pharmaceutical giant Johnson & Johnson’s first quarter earnings reported Tuesday morning. It was in many ways a repeat of a quarter earlier — only this time the numbers were worse with currency woes cutting further into international sales, profitability and now the company’s outlook on the coming […]

Read More »

Physicians Hail Senate Passage Of ‘Doc Fix’ As Value-Based Care Takes Hold

The U.S. Senate, following last month’s bipartisan action by the U.S. House of Representatives, tonight overwhelmingly passed a repeal of Medicare’s controversial sustainable growth rate formula. The vote, by a whopping 92-8 vote in the Senate, will avert a 21 percent cut in Medicare payments to doctors while at the same time moving future reimbursement […]

Read More »

How Obamacare Cost Squeeze May Push Rite Aid To Walgreens

Italian billionaire Stefano Pessina wasn’t ready this week to say Walgreens Boots Alliance (WBA) was prepared to buy Rite Aid (RAD), but he said more government influence on payments to pharmacies could spur rapid consolidation in the U.S. Now the top executive at Walgreens, Pessina speaks from experience having run Alliance Boots pharmacies in Europe […]

Read More »

Health data breaches on the rise

Large-scale health data breaches reported by doctors and health plans have been rising steadily, a new report shows. From 2010 to 2013, nearly 1000 large breaches affected more than 29 million individual health records, and more than half resulted from theft or loss of laptops, thumb drives and paper records, according to researchers with access […]

Read More »

Three Biotechs Well-Positioned for M&A: Gilead, Celgene, and Biogen

April 14, 2015By Riley McDermid, BioSpace.com Breaking News Sr. Editor The American biotech sector will see a continued boom in its merger and acquisition cycle after an unprecedented first quarter saw over $100 billion in deals, with companies like Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG), and Biogen, Inc. all poised to participate, said UBS […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom